Man Group
CBIO

Man Group’s Crescent Biopharma CBIO Stock Holding History

Man Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,499
Closed -$450K – 2109
2024
Q1 		$450K Buy
+1,499
New +$448K ﹤0.01% 1816
2022
Q4 		– Sell
-176
Closed -$10K – 2069
2022
Q3 		$10K Buy
+176
New +$12.6K ﹤0.01% 1981
2021
Q2 		– Sell
-279
Closed -$84K – 2003
2021
Q1 		$84K Sell
279
-292
-51% -$105K ﹤0.01% 1804
2020
Q4 		$215K Buy
+571
New +$200K ﹤0.01% 1724
2019
Q3 		– Sell
-4,955
Closed -$5.91M – 1832
2019
Q2 		$5.91M Sell
4,955
-510
-9% -$610K 0.02% 879
2019
Q1 		$6.81M Sell
5,465
-489
-8% -$560K 0.03% 752
2018
Q4 		$5.64M Buy
5,954
+1,834
+45% +$2.21M 0.03% 717
2018
Q3 		$5.93M Buy
4,120
+3,553
+627% +$5.37M 0.02% 895
2018
Q2 		$914K Buy
+567
New +$975K ﹤0.01% 1628

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group's CBIO Position: Q2 2024 in Review

Man Group sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 1,499 shares — an estimated $450K sold.

Man Group first reported a position in CBIO in Q2 2018 and held it in 9 quarters. The position peaked at $6.81M in Q1 2019. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • Man Group reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • Man Group sold 1,499 Crescent Biopharma shares in Q2 2024, an estimated $450K.
  • Man Group first reported a position in Crescent Biopharma in Q2 2018 and held it in 9 quarters.
  • Man Group's Crescent Biopharma position peaked at $6.81M in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.